Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Steadright Subsidiary NSM Capital Sarl Applies For License At Titanbeach One

Goliath Resources Accelerates Option Agreement On Golddigger While Reducing NSR

Related News

Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market...

Wednesday, April 28, 2021, 11:44:00 AM

Green Thumb: Analysts Upgrade Ratings On Back Of Earnings Beat

This morning Canaccord Genuity raised their 12-month price target on Green Thumb Industries (CSE: GTII)...

Thursday, November 12, 2020, 10:50:37 AM

Cresco Labs: Canaccord Lowers Target On Adjusted EBITDA Miss

On August 13, Cresco Labs (CSE: CL) announced its second quarter financials. The company had...

Thursday, August 19, 2021, 11:36:00 AM

Aphria: PI Financial Raises Price Target, Canaccord Reiterates Target

Last week, Aphria Inc (TSX: APHA) (NASDAQ: APHA) reported their year-end and fourth-quarter financial statements....

Sunday, August 2, 2020, 01:30:00 PM

BMO Reiterates Targets On Couche-Tard Despite Q2 Earnings Beat

On August 30, Alimentation Couche-Tard Inc. (TSX: ATD.B) announced its fiscal first quarter financial results...

Friday, September 2, 2022, 03:02:00 PM